KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Common Equity (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Common Equity for 8 consecutive years, with $218.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 7.93% to $218.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $218.8 million through Dec 2025, up 7.93% year-over-year, with the annual reading at $218.8 million for FY2025, 7.93% up from the prior year.
  • Common Equity hit $218.8 million in Q4 2025 for Adaptive Biotechnologies, up from $204.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $725.7 million in Q1 2021 to a low of $179.5 million in Q2 2025.
  • Historically, Common Equity has averaged $396.2 million across 5 years, with a median of $378.8 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 31.57% in 2021 and later tumbled 39.03% in 2024.
  • Year by year, Common Equity stood at $604.1 million in 2021, then fell by 23.18% to $464.1 million in 2022, then plummeted by 33.57% to $308.3 million in 2023, then plummeted by 34.24% to $202.7 million in 2024, then grew by 7.93% to $218.8 million in 2025.
  • Business Quant data shows Common Equity for ADPT at $218.8 million in Q4 2025, $204.4 million in Q3 2025, and $179.5 million in Q2 2025.